How Ozempic and Wegovy work — mechanism comparison
Ozempic and Wegovy contain the same active ingredient (semaglutide), so they work through the same molecular pathway. The differences are in dosing, FDA-approved indications, and labeling — not in how the drug acts on your body. Both bind to GLP-1 receptors, slow gastric emptying, increase insulin secretion in response to meals, and signal satiety to the brain.
This shared mechanism matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Ozempic mechanism guide and Wegovy mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Ozempic: 6% at 40 weeks (trial: SUSTAIN)
- Wegovy: 14.9% at 68 weeks (trial: STEP-1)
Wegovy produced 8.9 percentage points more weight loss than Ozempicin head-to-head comparison. Note that trials weren't conducted head-to-head — these are separate trial endpoints in different populations. Real-world differences may be smaller. Individual variability is also large.
Side-by-side radar: Ozempic vs Wegovy
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Ozempic | Wegovy |
|---|---|---|
| Efficacy | 7 | 8 |
| Convenience | 9 | 9 |
| Affordability | 6 | 6 |
| Tolerance | 5 | 5 |
| Evidence | 10 | 10 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Side-effect rate comparator
Trial-derived adverse-event rates with placebo delta. Sourced from FDA-approved labels for each drug. Most sources omit placebo rates entirely.
| Adverse event | Ozempic | Wegovy |
|---|---|---|
| Nausea | 20%(placebo 6%) +14.0 pp vs placebo | 44%(placebo 16%) +28.0 pp vs placebo |
| Diarrhea | 9%(placebo 4%) +5.0 pp vs placebo | 30%(placebo 16%) +14.0 pp vs placebo |
| Vomiting | 9%(placebo 2%) +7.0 pp vs placebo | 24%(placebo 6%) +18.0 pp vs placebo |
| Constipation | 5%(placebo 2%) +3.0 pp vs placebo | 24%(placebo 11%) +13.0 pp vs placebo |
| Abdominal pain | — | 20%(placebo 10%) +10.0 pp vs placebo |
| Headache | — | 14%(placebo 12%) +2.0 pp vs placebo |
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Ozempic and Wegovy.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Ozempic
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9+: 1 mg
- If needed: 2 mg
Wegovy
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13+: 1.7–2.4 mg
See full titration guides for Ozempic dosing and Wegovy dosing.
Cost comparison
Cost differences between Ozempic and Wegovy depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Ozempic): $968/month
- Average retail price (Wegovy): $1349/month
- Ozempic savings card: as low as $25/month for eligible commercial-insured
- Wegovy savings card: as low as $0/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Ozempic vs Wegovy, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Ozempic cost guide · Wegovy cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Ozempic if…
- Your insurance covers it but not Wegovy
- Your prescriber has more experience with it
Choose Wegovy if…
- Your insurance covers it but not Ozempic
- Your prescriber has more experience with it
- Maximum weight loss is your priority (higher mean efficacy)
Switching from Ozempic to Wegovy (or vice versa)
Because Ozempic and Wegovy contain the same active ingredient, switching between them is relatively simple — your prescriber can often transition you at the dose-equivalent point without re-titration. Common reasons to switch include insurance formulary changes, different FDA-approved indications, or different dose ranges (e.g., Wegovy goes higher than Ozempic; Zepbound and Mounjaro have different labeled indications despite identical active ingredient).
FAQ — Ozempic vs Wegovy
Are Ozempic and Wegovy the same drug?
Yes — both contain semaglutide. They differ in FDA-approved indications, dose ranges, and labeling, but the active ingredient is identical.
Which is more effective for weight loss, Ozempic or Wegovy?
In separate pivotal trials, Wegovy produced 8.9 percentage points more weight loss than Ozempic on average. However, these were separate trials with different populations — not a head-to-head comparison. Individual response variability is also large; most patients achieve clinically meaningful weight loss with either drug.
Can I take Ozempic and Wegovy together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine them.
Which has fewer side effects, Ozempic or Wegovy?
Side-effect profiles are broadly similar across GLP-1 medications — primarily GI effects that fade with adaptation. Individual tolerance varies. Trial data shows comparable rates of nausea, diarrhea, and other common effects between Ozempic and Wegovy.
Will my insurance cover Ozempic but not Wegovy?
Often the coverage differs. Insurance formularies are negotiated separately per drug — Ozempic may be on Tier 2 of your plan while Wegovy is Tier 4 or excluded. Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.